The effects of Lumbricus rubellus extract on Staphylococcus aureus colonization and IL-31 levels in children with atopic dermatitis

Phase 1

Completed

• Conditions: Patient with atopic dermatitis; antiallergic agent; antimicrobial activity; Lumbricus rubellus; atopic dermatitis; IL-31

• Registration Number: TCTR20231025004
• Lead Sponsor: niversitas Syiah Kuala (The Ministry of Education, Culture, Research and Technology)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-25
• Study Completion: 2024-02-29
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

(1) AD patients with Scoring Atopic Dermatitis (SCORAD) index > 25 and meeting the Hanifin and Rajka criteria, (2) aged 8-16 years old, (3) total serum IgE level >100 IU/mL, (4) healthy weight (5th-85th percentile) children based on the CDC BMI-for-age (2-20 years old) growth chart

Exclusion Criteria

1) treated with steroid, systemic antihistamine, or phototherapy in the last month and systemic immunosuppressive therapy in the last three months, (2) obtained systemic antibiotic in the last one month, (3) used topical antibiotic or antiseptic soap in the last two weeks, (4) had immunosuppressive or systemic diseases, and (5) positive feces identification for intestinal nematode parasites (e.g., Ascaris lumbricoides, Enterobius vermicularis)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Staphylococcus aureus colonization The patients were evaluated after fourteen days. catalase test, coagulase test, and MSA media

Secondary Outcome Measures

Name	Time	Method
IL-31 levels The patients were evaluated after fourteen days. ELISA assay